More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
A comprehensive report on encephalitis clinical trials has been added to ResearchAndMarkets.com's offering, providing data on trial numbers, enrollment trends, and geographic distribution across G7 and E7 countries.
China Medical System Holdings partnered with Insilico Medicine on AI-powered drug discovery in early February 2026 and received Chinese regulatory approval to begin human trials for complement factor B inhibitor CMS-D017.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07393074 |
PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC) |
RECRUITING | NA |
| NCT06680531 |
A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05627986 |
Sensorimotor Cortex Excitability in Shoulder Impingement Syndrome |
COMPLETED | |
| NCT04846764 |
Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM) |
UNKNOWN | NA |
| NCT04644315 |
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors |
TERMINATED | PHASE2 |
| NCT04014491 |
The Effects of Exercise Training on Corticospinal System in Overhead Athletes With Shoulder Impingement Syndrome |
COMPLETED | NA |
| NCT03830762 |
Xanamem™ in Healthy Elderly Subjects |
COMPLETED | PHASE1 |
| NCT03430427 |
Brain Networks and Mobility Function: B-NET |
COMPLETED | |
| NCT03268239 |
Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions |
COMPLETED | NA |
| NCT02652260 |
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) |
COMPLETED | PHASE2 |
